Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019
April 30 2019 - 4:05PM
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage
biopharmaceutical company focused on the development and
commercialization of innovative therapeutics, today announced the
Company will host a conference call and live audio webcast on
Wednesday, May 8, 2019 at 4:30 p.m. EDT to report its first quarter
ended March 31, 2019 financial results and provide a corporate
update. The audio webcast can be accessed under "Events and
Presentations" in the Investor Relations section of the Company's
website at www.ParatekPharma.com. Domestic investors wishing to
participate in the call should dial: 877-407-0792 and international
investors should dial: 201-689-8263. The conference ID is 13690427.
Investors can also access the call at
http://public.viavid.com/index.php?id=134405.
About Paratek
Pharmaceuticals, Inc.Paratek Pharmaceuticals, Inc. is
a commercial-stage biopharmaceutical company focused on the
development and commercialization of innovative therapeutics. The
company’s lead commercial product, NUZYRA™ (omadacycline), which
has launched and is available in the U.S., is a once-daily
oral and intravenous antibiotic for the treatment of adults with
community-acquired bacterial pneumonia and acute bacterial skin and
skin structure infections. Paratek is also studying NUZYRA for the
treatment of urinary tract infections (UTI). Paratek has
submitted a marketing authorization application of omadacycline in
the European Union. Paratek has entered into a collaboration
agreement with Zai Lab for the development and
commercialization of omadacycline in the
greater China region and retains all remaining global
rights. Under a research agreement with the U.S. Department of
Defense, omadacycline also is being studied against pathogenic
agents causing infectious diseases of public health and biodefense
importance, including plague and anthrax. SEYSARA™ (sarecycline) is
an FDA-approved product with respect to which we have
exclusively licensed certain rights in the United
States to Almirall, LLC, or Almirall. SEYSARA is
currently being marketed by Almirall in the U.S. as a new
once-daily oral therapy for the treatment of moderate to severe
acne vulgaris. Paratek retains development and commercialization
rights with respect to sarecycline in the rest of the world.
Recognizing the serious threat of bacterial infections,
Paratek is dedicated to providing solutions that enable
positive outcomes and lead to better patient stories. For more
information, visit www.ParatekPharma.com or follow
@ParatekPharma on Twitter.
Forward Looking
StatementsThis press release contains forward-looking
statements including statements related to our overall strategy,
product candidates, clinical studies, prospects,
potential and expected results, including statements about
the timing of commercialization of NUZYRA, the
potential for omadacycline to serve as an empiric monotherapy
treatment option for patients suffering from ABSSSI, CABP, and
potentially UTI, and other bacterial infections when
resistance is of concern, the prospect of omadacycline providing
broad-spectrum activity, and our ability to make and sell
NUZYRA. All statements, other than statements of historical
facts, included in this press release are forward-looking
statements, and are identified by words such as “advancing,”
“believe,” “expect,” “well positioned,” “look forward,”
“anticipated,” “continued,” and other words and terms of
similar meaning. These forward-looking statements are based upon
our current expectations and involve substantial risks and
uncertainties. We may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance
on these forward-looking statements. Our actual results and the
timing of events could differ materially from those included in
such forward-looking statements as a result of these risks and
uncertainties. These and other risk factors are discussed under
"Risk Factors" and elsewhere in our Annual Report on Form 10-K for
the year ended December 31, 2018 and our other filings with the
Securities and Exchange Commission. We expressly disclaim any
obligation or undertaking to update or revise any forward-looking
statements contained herein.
CONTACT:
Investor and Media
Relations: |
|
|
Ben Strain |
|
|
617-807-6688 |
|
|
ir@ParatekPharma.com |
|
|
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2023 to Apr 2024